News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
688,086 Results
Type
Article (39150)
Company Profile (283)
Press Release (648653)
Section
Business (203903)
Career Advice (1996)
Deals (35372)
Drug Delivery (89)
Drug Development (80852)
Employer Resources (168)
FDA (16099)
Job Trends (14808)
News (344646)
Policy (32450)
Tag
Academia (2530)
Alliances (49187)
Alzheimer's disease (1262)
Approvals (16066)
Artificial intelligence (146)
Bankruptcy (352)
Best Places to Work (11582)
Biotechnology (200)
Breast cancer (190)
Cancer (1381)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (283)
Clinical research (64718)
Collaboration (486)
Compensation (264)
COVID-19 (2542)
C-suite (109)
Data (1396)
Diabetes (177)
Diagnostics (6171)
Earnings (84898)
Employer resources (146)
Events (110021)
Executive appointments (397)
FDA (16794)
Funding (434)
Gene therapy (197)
GLP-1 (599)
Government (4333)
Healthcare (18697)
Infectious disease (2635)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16347)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7864)
Lung cancer (200)
Manufacturing (207)
Medical device (13214)
Medtech (13219)
Mergers & acquisitions (19199)
Metabolic disorders (461)
Neuroscience (1586)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1709)
Obesity (262)
Opinion (183)
Parkinson's disease (98)
Patents (121)
People (56465)
Phase I (20133)
Phase II (28500)
Phase III (21244)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (264)
Real estate (5891)
Regulatory (21690)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1472)
Startups (3562)
United States (15278)
Vaccines (564)
Weight loss (182)
Date
Today (19)
Last 7 days (129)
Last 30 days (2043)
Last 365 days (35193)
2024 (35193)
2023 (40076)
2022 (51173)
2021 (55710)
2020 (54086)
2019 (46542)
2018 (35019)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (196)
Asia (37286)
Australia (6088)
California (3843)
Canada (1461)
China (313)
Colorado (173)
Connecticut (179)
Europe (79844)
Florida (538)
Georgia (136)
Illinois (387)
Indiana (226)
Maryland (638)
Massachusetts (2980)
Michigan (175)
Minnesota (292)
New Jersey (1113)
New York (1095)
North Carolina (743)
Northern California (1709)
Ohio (146)
Pennsylvania (930)
South America (1092)
Southern California (1472)
Texas (555)
Utah (108)
Washington State (401)
688,086 Results for "erasca inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Erasca to Present at Upcoming Investor Conferences
November 5, 2024
·
1 min read
Business
Erasca Reports First Quarter 2024 Business Updates and Financial Results
Erasca, Inc. provided business updates and reported financial results for the fiscal quarter ended March 31, 2024.
May 8, 2024
·
10 min read
Biotech Beach
Erasca to Present at Upcoming Investor Conferences in June 2024
Erasca, Inc. announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings.
May 29, 2024
·
1 min read
Drug Development
Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
Erasca, Inc. announced it has entered into exclusive license agreements for two preclinical RAS programs—a potential best-in-class pan-RAS molecular glue and a potential first-in-class pan-KRAS inhibitor —and provided a pipeline update.
May 16, 2024
·
10 min read
Press Releases
Erasca Reports Third Quarter 2024 Business Updates and Financial Results
November 12, 2024
·
10 min read
Drug Development
Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma
Erasca, Inc. today announced the initiation of the global SEACRAFT-2 Phase 3 trial evaluating the pan-RAF inhibitor naporafenib in combination with the MEK inhibitor trametinib (MEKINIST®) in patients with NRAS-mutant (NRASm) melanoma.
June 18, 2024
·
7 min read
Biotech Beach
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting
Erasca, Inc. announced the company will present one oral presentation and two poster presentations at the upcoming American Society of Clinical Oncology Annual Meeting, taking place May 31-June 4, 2024, in Chicago, Illinois.
April 24, 2024
·
5 min read
Biotech Beach
Erasca Announces Pricing of Underwritten Offering of Common Stock - May 17, 2024
Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share.
May 16, 2024
·
4 min read
Press Releases
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise
October 25, 2024
·
10 min read
Biotech Beach
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Erasca, Inc. announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional shares.
May 21, 2024
·
3 min read
1 of 68,809
Next
